Finally Time To Cut Your Stake? Ladenburg Thalmann Downgrades Genomic Health (GHDX) Shares

June 13, 2018 - By Marguerite Chambers

Genomic Health, Inc. (NASDAQ:GHDX) Logo

Investors sentiment increased to 1.42 in 2018 Q1. Its up 0.29, from 1.13 in 2017Q4. It improved, as 16 investors sold Genomic Health, Inc. shares while 29 reduced holdings. 24 funds opened positions while 40 raised stakes. 31.06 million shares or 0.50% less from 31.21 million shares in 2017Q4 were reported.

Bancorporation Of America Corp De reported 0% in Genomic Health, Inc. (NASDAQ:GHDX). Ameritas Investment Prtn Inc holds 1,734 shares or 0% of its portfolio. Massachusetts Finance Ser Ma accumulated 14,447 shares. Oppenheimer & Inc has 0.06% invested in Genomic Health, Inc. (NASDAQ:GHDX) for 71,626 shares. Cubist Systematic Strategies Limited Com has 0% invested in Genomic Health, Inc. (NASDAQ:GHDX). The Illinois-based Citadel Advisors Llc has invested 0% in Genomic Health, Inc. (NASDAQ:GHDX). Stratos Wealth Prtn Ltd holds 0% of its portfolio in Genomic Health, Inc. (NASDAQ:GHDX) for 30 shares. Grp Incorporated One Trading Ltd Partnership reported 420 shares. Raymond James & Assocs invested 0% in Genomic Health, Inc. (NASDAQ:GHDX). Schwab Charles Invest Mngmt invested 0.01% in Genomic Health, Inc. (NASDAQ:GHDX). Goldman Sachs Grp Inc holds 0% or 422,005 shares. Invesco Ltd stated it has 0% of its portfolio in Genomic Health, Inc. (NASDAQ:GHDX). Federated Investors Pa owns 1,388 shares. Pnc Financial Services Group Inc invested 0% in Genomic Health, Inc. (NASDAQ:GHDX). California Pub Employees Retirement accumulated 61,500 shares or 0% of the stock.

Since December 14, 2017, it had 0 buys, and 15 selling transactions for $7.32 million activity. Leber Laura also sold $699,000 worth of Genomic Health, Inc. (NASDAQ:GHDX) on Thursday, December 14. Cole G Bradley sold $164,474 worth of stock or 5,000 shares. Febbo Phillip G. had sold 4,942 shares worth $162,290. Shares for $160,048 were sold by Popovits Kimberly J on Wednesday, March 14. Vaughn James J sold $102,406 worth of Genomic Health, Inc. (NASDAQ:GHDX) on Tuesday, January 2.

Genomic Health (GHDX) Receives a Downgrade

Ladenburg Thalmann decreased their rating for shares of Genomic Health (GHDX) from “Buy” to “Neutral” in analysts note that was sent to investors on Wednesday, 13 June.

The stock decreased 1.66% or $0.84 during the last trading session, reaching $49.86. About 129,729 shares traded. Genomic Health, Inc. (GHDX) has risen 30.62% since June 13, 2017 and is uptrending. It has outperformed by 18.05% the S&P500.

Analysts await Genomic Health, Inc. (NASDAQ:GHDX) to report earnings on August, 7. They expect $0.07 earnings per share, up 187.50 % or $0.15 from last year’s $-0.08 per share. GHDX’s profit will be $2.48 million for 178.07 P/E if the $0.07 EPS becomes a reality. After $0.13 actual earnings per share reported by Genomic Health, Inc. for the previous quarter, Wall Street now forecasts -46.15 % negative EPS growth.

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company has market cap of $1.76 billion. It develops and commercializes genomic clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. It currently has negative earnings. The firm offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit.

More important recent Genomic Health, Inc. (NASDAQ:GHDX) news were published by: which released: “New data reinforce positive impact of the Oncotype DX GPS test in guiding treatment decisions” on May 21, 2018, also published article titled: “Pre-Open Movers 06/04: (VSAR) (VYGR) (GHDX) Higher; (NKTR) (JNCE) (CFX) Lower (more…)”, published: “Here’s Why Genomic Health Rocketed Higher Today” on June 04, 2018. More interesting news about Genomic Health, Inc. (NASDAQ:GHDX) was released by: and their article: “Top Analyst Upgrades and Downgrades: Applied Materials, Comcast, HUYA, Sprint, Time Warner, Yelp and More” with publication date: June 13, 2018.

Genomic Health, Inc. (NASDAQ:GHDX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.